Brokerages Expect Tandem Diabetes Care Inc (TNDM) Will Post Quarterly Sales of $56.15 Million

Analysts expect Tandem Diabetes Care Inc (NASDAQ:TNDM) to report sales of $56.15 million for the current fiscal quarter, according to Zacks. Four analysts have made estimates for Tandem Diabetes Care’s earnings. The lowest sales estimate is $54.70 million and the highest is $57.03 million. Tandem Diabetes Care reported sales of $40.29 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 39.4%. The company is scheduled to issue its next quarterly earnings results on Thursday, March 7th.

On average, analysts expect that Tandem Diabetes Care will report full-year sales of $163.81 million for the current year, with estimates ranging from $162.30 million to $164.70 million. For the next year, analysts forecast that the business will post sales of $217.16 million, with estimates ranging from $211.10 million to $228.70 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Tandem Diabetes Care.

Tandem Diabetes Care (NASDAQ:TNDM) last released its quarterly earnings results on Thursday, November 1st. The medical device company reported ($0.62) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.28). Tandem Diabetes Care had a negative net margin of 93.07% and a negative return on equity of 204.32%. The company had revenue of $46.30 million during the quarter, compared to analyst estimates of $42.71 million. During the same quarter last year, the business earned ($3.09) EPS. The company’s revenue for the quarter was up 71.5% compared to the same quarter last year.

A number of equities analysts recently weighed in on the company. Oppenheimer set a $57.00 price target on Tandem Diabetes Care and gave the company a “buy” rating in a research report on Friday. BidaskClub lowered Tandem Diabetes Care from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. Lake Street Capital set a $60.00 price target on Tandem Diabetes Care and gave the company a “buy” rating in a research report on Saturday, November 3rd. Craig Hallum set a $59.00 price target on Tandem Diabetes Care and gave the company a “buy” rating in a research report on Friday, November 2nd. Finally, Zacks Investment Research lowered Tandem Diabetes Care from a “buy” rating to a “hold” rating in a research report on Saturday, October 6th. Four investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $44.27.

NASDAQ:TNDM opened at $37.19 on Wednesday. Tandem Diabetes Care has a 1-year low of $2.14 and a 1-year high of $52.55.

In other Tandem Diabetes Care news, Director Richard P. Valencia acquired 1,300 shares of the firm’s stock in a transaction on Monday, November 5th. The stock was purchased at an average cost of $37.75 per share, for a total transaction of $49,075.00. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Kim D. Blickenstaff sold 198,000 shares of the firm’s stock in a transaction dated Wednesday, November 7th. The stock was sold at an average price of $37.01, for a total value of $7,327,980.00. The disclosure for this sale can be found here. Company insiders own 9.30% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Northern Trust Corp acquired a new stake in shares of Tandem Diabetes Care in the first quarter worth $415,000. JPMorgan Chase & Co. acquired a new stake in shares of Tandem Diabetes Care in the first quarter worth $593,000. A.R.T. Advisors LLC increased its stake in shares of Tandem Diabetes Care by 284.4% in the first quarter. A.R.T. Advisors LLC now owns 38,518 shares of the medical device company’s stock worth $191,000 after acquiring an additional 28,499 shares during the period. Millennium Management LLC acquired a new stake in shares of Tandem Diabetes Care in the first quarter worth $4,225,000. Finally, Royal Bank of Canada increased its stake in shares of Tandem Diabetes Care by 2,375,000.0% in the first quarter. Royal Bank of Canada now owns 47,502 shares of the medical device company’s stock worth $236,000 after acquiring an additional 47,500 shares during the period. Hedge funds and other institutional investors own 62.80% of the company’s stock.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Featured Story: How to calculate compound interest

Get a free copy of the Zacks research report on Tandem Diabetes Care (TNDM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply